The use of other growth factors has been trialed in ARDS without success, with systemic-44 or lung-delivered45 granulocyte–macrophage colony-stimulating factor (GM-CSF) failing to improve ARDS mortality. Here, CSF2 is linked to acute respiratory distress syndrome.